Editors' ChoiceCancer

CRISPR-engineered immune cells reach the bedside

See allHide authors and affiliations

Science Translational Medicine  13 May 2020:
Vol. 12, Issue 543, eabb7095
DOI: 10.1126/scitranslmed.abb7095

Abstract

In a clinical trial, CRISPR editing of T cells to fight lung cancer was feasible and safe.

View Full Text

Stay Connected to Science Translational Medicine